Data follow the approval of the world's first self-amplifying (sa-mRNA) COVID-19 vaccine for adults in Japan. These results add to recently published data on ARCT-154 demonstrating superior...

Australia’s newest biotech incubator Jumar Bioincubator has officially opened its doors and revealed the first 16 innovative early-stage ventures to take up residency in its much-awaited Melbourne-based facility at an event officiated by Lord Mayor, Sally Capp AO.

Strong CSL Behring portfolio growth especially Ig FINANCIAL HIGHLIGHTS4 Revenue $8.05 billion, up 11% at CC3 NPAT $1.90 billion1, up 17% NPAT $1.94 billion1 at CC3, up 20% NPATA $2.02 billion1,2 ,...

Global biotechnology leader CSL (ASX:CSL; USOTC:CSLLY) today announced top-line results from the Phase 3 AEGIS-II trial evaluating the efficacy and safety of CSL112 (apolipoprotein A-I [human])...

Study conducted by Meiji Seika Pharma in Japan Short communication follows previously published data in The Lancet Infectious Diseases demonstrating Immunological Non-Inferiority to Wuhan Strain...

CSL's HEMGENIX® is a one-time, single-dose treatment for male adults with severe/moderately severe hemophilia B BERN, Switzerland, Jan. 15, 2024 /PRNewswire/ -- Global biotechnology leader CSL...

Study conducted by Meiji Seika Pharma in Japan Data follow approval of the world's first self-amplifying messenger RNA (sa-mRNA) COVID-19 vaccine for adults by Japan Ministry of Health, Labor and...

These regulatory milestones bring CSL one step closer to delivering on our promise to patients with a first-in-class recombinant monoclonal antibody for people living with HAE, a community CSL has...

HEMGENIX® is the first and only gene therapy approved by the U.S. Food and Drug Administration (FDA) for the treatment of hemophilia B and to show sustained efficacy and safety at three years...

Exclusive Partner in Japan, Meiji Seika Pharma advances regulatory approval This historic approval of the world's first Self-Amplifying messenger RNA (sa-mRNA) COVID-19 Vaccine underscores CSL's...

HEMGENIX®, the first and only FDA-approved gene therapy for adults with hemophilia B, wins for Best Product for Rare/Orphan Diseases KING OF PRUSSIA, Pa. and LEXINGTON, Mass., Oct. 27, 2023...

Global biotechnology leader CSL (ASX: CSL) today announced that Health Canada has authorized HEMGENIX® (etranacogene dezaparvovec), the first and only gene therapy for the treatment of hemophilia...

Global biotechnology leader CSL (ASX: CSL; USOTC: CSLLY) announced today that it has signed a Renewable-Linked Power Purchase Agreement (PPA) with Australian energy provider, AGL. AGL was awarded...

MELBOURNE – 12 October 2023 – Two Australian scientists have each been awarded CSL Centenary Fellowships, valued at $1.25 million over five years. They are each developing new kinds of...

MELBOURNE, AUSTRALIA – 04 October 2023 – CSL’s Research Acceleration Initiative (RAI) continues to expand its reach with seven medical researchers awarded new RAI partnerships, including up...

EMA application supported by Phase 3 primary vaccination study demonstrating primary efficacy endpoint was met An additional Phase 3 booster study demonstrating non-inferiority of immune response...

Melbourne, Australia – 21 August 2023 – Australia today ushered in a new era in scientific and medical innovation, with Prime Minister of Australia, Anthony Albanese officially opening CSL’s...

Global biotechnology leader CSL (ASX: CSL) (USOTC: CSLLY) announced today that Jeffrey Ball, an established global leader across multiple disciplines and functions, has been appointed Chief...

The site will support CSL's growing R&D portfolio, accelerating the development of next-generation mRNA technology for vaccines WALTHAM, Mass., March 27, 2023 /PRNewswire/ -- Global biotechnology...

Significant reduction in number of attacks support the potential of once-monthly garadacimab as a prophylactic therapy for patients with hereditary angioedema KING OF PRUSSIA, Pa., March 1, 2023...

Majority of patients were attack free during the entire six-month treatment period (61.5%) Study results presented for first time at 2023 AAAAI Annual Meeting; global regulatory submissions...

Data follow the historic approval of the first gene therapy for hemophilia B, which reduces the rate of annual bleeds, reduces or eliminates the need for prophylactic therapy and generates...

CSL recognized in Forbes and Statista's Best Large-sized Employer category for the fourth time since 2018. KING OF PRUSSIA, Pa., Feb. 21, 2023 /PRNewswire/ -- Global biotechnology leader CSL has...

HEMGENIX® underscores CSL's promise to deliver life-changing innovations that have the potential to help patients lead full lives MARBURG, Germany, Feb. 20, 2023 /PRNewswire/ -- Global...

Global biotechnology leader CSL (ASX: CSL) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending conditional marketing authorization (CMA) of etranacogene dezaparvovec.

Dr Paul McKenzie appointed Chief Executive Officer and Managing Director of CSL from 6 March 2023 MELBOURNE, Australia, Dec. 12, 2022 /PRNewswire/ -- The Board of Directors of CSL Limited...

Long-term data from the pivotal HOPE-B study show a one-time infusion of HEMGENIX generated elevated and sustained mean factor IX levels and reduced the rate of annual bleeding 24-month results...

Global biotechnology leader CSL (ASX: CSL) today announced that the U.S. Food and Drug Administration (FDA) approved HEMGENIX® (etranacogene dezaparvovec-drlb), the first and only one-time gene therapy for appropriate adults with hemophilia B.

CSL, WEHI, and the University of Melbourne today announced the appointment of an independent operator to oversee and manage the new start-up incubator which will support and grow early-stage Australian biotech companies, providing both lab and office spaces.

Pipeline advancements and investment in innovation and disruptive technologies to help fuel sustainable, profitable growth for CSL's three businesses, CSL Behring, CSL Seqirus and CSL Vifor, in...

CSL Limited (ASX:CSL; USOTC:CSLLY) today announces that its subsidiary, CSL Seqirus, has entered into a collaboration and license agreement with Arcturus Therapeutics Holdings Inc ("Arcturus...

Global biotechnology leader CSL (ASX:CSL; USOTC:CSLLY), today announced the company has entered into a Strategic Option and License Agreement with Arizona-based Translational Sciences for their enhanced thrombus dissolving drug candidate, TS23.

Global biotechnology leader CSL’s new global corporate headquarters has been awarded a five-star rating from the Green Building Council of Australia.

Global biotherapeutics leader CSL today announced that two Australian scientists have each been awarded a CSL Centenary Fellowship of $1.25 million over five years.

CSL Extends Reach of Global Research Acceleration Initiative with Freshly Inked Partnerships to Fast-Track Research Programs

Bernadette Murdoch, an experienced Australian and global corporate affairs and communications leader across multiple industries, will join CSL and lead its global Reputation Management Center of...

The new facility, once fully open later this calendar year, will be CSL's largest R&D site under one roof, with more than 500 team members working in a state-of-the-art facility offering access to...

CSL Limited (ASX: CSL) Today, CSL advances its vision for a more sustainable future by setting new, tangible targets for carbon emissions reductions. As part of the company's broader...

All business units will incorporate CSL name and branding to signify one company MELBOURNE, Australia, Aug. 10, 2022 /PRNewswire/ -- Global biotech leader CSL today announced that all business...

Statement attributable to Greg Boss, Executive Vice President - Legal, and CSL Limited Group General Counsel. 11 May 2022 We are encouraged by the United States Court of Appeals for the District...

CSL ranked fourth on the Health Industry list, from a total of more than 750 organisations nominated in all sectors across Australia and New Zealand. MELBOURNE, 27, April: Today, CSL is honoured...

With 25,000 global employees, CSL is one of 500 Large Employers recognized across 25 industry sectors KING OF PRUSSIA, Pa., 2 March 2022 – Forbes Magazine has named global biotechnology leader...

CSL Behring AG Publishes Offer Prospectus On Public Tender Offer For All Publicly Held Shares Of Vifor Pharma Ltd. MELBOURNE, Australia and ST. GALLEN, Switzerland. CSL Behring AG, Berne,...

Agreement Announced on the Australian Stock Exchange and SIX Swiss Exchange 14 December, 2021 Expands CSL’s leadership across an attractive portfolio focused on Renal Disease, and Iron...

Melbourne, 14 December 2021 – CSL Limited (ASX:CSL) and its vaccine business, Seqirus, today reaffirms a strong commitment to accelerating its proprietary next-generation self-amplifying mRNA...

Through the StartX partnership, CSL will access an ecosystem of early stage biotech, medtech and digital healthcare ventures, exploring opportunities to collaborate around disruptive technologies...

- CSL, WEHI and The University of Melbourne have secured funding to join forces and create an incubator and commercial wet lab space for biotech start-up companies - The project partners are...

Faster treatments for future pandemics (Brisbane) Investigating the DNA factory in our bodies that makes everything (Melbourne) MELBOURNE and BRISBANE; October 27, 2021: Two Australian scientists...

MELBOURNE, AU and KING OF PRUSSIA, PA; October 19/18, 2021: Two of Melbourne’s most prominent medical research and drug development organisations, WEHI and CSL, have joined forces to create a...

CSL Reaffirms Commitment to Manufacture AstraZeneca COVID Vaccine into 2022 Melbourne, Australia: CSL is committed to the manufacture of approximately 50 million doses of the AstraZeneca COVID-19...

CSL Requires COVID-19 Vaccination for On-Site Employees and Visitors Melbourne, Australia: CSL has confirmed all Australian on-site employees, contractors and visitors will be required to be...

CSL confirms there was a positive COVID-19 case at its Broadmeadows manufacturing facility last week. All employees and contractors who were present at the same time as the confirmed case have...

$2.5 Million Funding Available to Australian Biomedical Researchers Melbourne, Australia: 01.06.2021: Australia’s top biomedical researchers are invited to apply for one of two CSL Centenary...

New Patent Box policy will benefit domestic commercialisation of medical research Melbourne, Australia: CSL welcomes the Federal Government’s Budget commitment to introduce a Patent Box that...

Onshore mRNA manufacturing will build Australian capability for next generation vaccine technologies Melbourne, Australia: CSL welcomes the Government’s plan to further develop onshore mRNA...

Etranacogene dezaparvovec (AMT-061) is an investigational gene therapy that may potentially provide people with hemophilia B with years of functional levels of Factor IX, a blood-clotting protein...

Melbourne, Australia: CSL can confirm that production of the AstraZeneca COVID-19 vaccine for Australia has reached more than a million doses a week - these volumes have been produced for a number...

Four Australian Research Programs to be Fast-Tracked in Partnership with CSL Melbourne, Australia: Four Australian medical researcher programs have been awarded a CSL Research Acceleration...

CSL remains committed to meeting its contracted arrangements with the Australian Government and AstraZeneca for locally produced AstraZeneca COVID-19 vaccines. We will continue our focused and...

CSL continues to provide medicines to patients around the world. Safeguarding our people, patients and donors remains our top priority. As the COVID-19 pandemic evolves, CSL continues to provide...

Here is how CSL is working around the world with academia, industry and governments to combat the novel coronavirus COVID-19 CSL and AstraZeneca have agreed for CSL to manufacture approximately 50...

Melbourne, 24 March 2021 – CSL Limited (ASX:CSL) has released 830,000 locally made doses of the AstraZeneca COVID-19 vaccine, ahead of initial scheduling. The release follows the completion of...

CSL is pleased to confirm that the final stages of manufacturing of the AstraZeneca COVID-19 vaccine for Australia are planned to commence next week, with first doses on track for release towards...

24 healthy volunteers to be recruited for study of plasma-derived COVID-19 Immunoglobulin January 31, 2021, Melbourne: CSL Behring Australia, a subsidiary of CSL Limited, today announced that...

CSL Commences Manufacturing of University of Oxford/AstraZeneca Vaccine Candidate in Melbourne. November 8, 2020, Melbourne — CSL Limited (ASX:CSL) CSL today confirmed it will commence...

Two Australian scientists have each been awarded CSL Centenary Fellowships, valued at $1.25 million over five years, to investigate new ways to fight two of the world’s biggest health...

October 8, 2020, Melbourne — CSL Limited (ASX:CSL; USOTC:CSLLY) today announces that its subsidiary, Seqirus, has signed a final agreement (Agreement) with the Commonwealth of Australia for the...

CSL has appointed Ms Joy Linton, a well-respected global leader with extensive strategic and financial experience as Chief Financial Officer (CFO.) Ms Linton will be based at CSL’s Head Office...

CSL Limited (ASX:CSL) today announced it has signed a Heads of Agreement (HoA) with the Australian Government for the supply of 51 million doses of the University of Queensland’s (UQ) COVID-19...

Development of the University of Queensland’s vaccine candidate remains CSL’s priority. However, we are currently in discussions with AstraZeneca and the Australian Government to assess...

Washington, D.C., July 30, 2020 – At today’s White House Roundtable, plasma industry leader and CSL CEO Paul Perreault urged people who have recovered from COVID-19 to consider donating plasma...

The report made by the Courier Mail and other media agencies today that an agreement has been struck to specifically secure supply, when a vaccine is available, for Queensland, is incorrect. In...

Economist Intelligence Unit (EIU) Report launched today reveals only one in three rare disease patients receives the best-available, evidence-based care. Less than a third of surveyed healthcare...

Today, the first human trials using the University of Queensland’s (UQ) COVID-19 vaccine have commenced in Australia The first human trials using the University of Queensland’s (UQ) COVID-19...

Applications are now open for the 2021 CSL Centenary Fellowships, which are offered to outstanding mid-career scientists seeking to undertake world-class medical research at an Australian academic...

Plasma-derived therapeutic with potential to treat serious complications of COVID-19. MELBOURNE, AUSTRALIA – CSL Behring Australia, a subsidiary of CSL Limited, today announced that it will...

To speed treatments, global biotech leader CSL offers to lend the company’s expertise in science and manufacturing. Anthony Farina – Chief Communications Officer, CSL Limited 18 Mar 2020 As...

CSL Limited's statement on Coronavirus Coronavirus is quite different to influenza virus so it is not a core area of focus for CSL or Seqirus. However, we have investigated possible adjacencies in...

Forbes Magazine named CSL among its Best Employers for Diversity 2020. The annual rankings, which measure diversity across six different categories, are based on an independent survey of more than...

The Honourable John Brumby AO today formally opened the new ‘Nancy Millis’ building, an expansion of the Bio21 Institute of Molecular Science and Biotechnology, University of Melbourne,...

CSL statement in response to media reports on case against Joseph Chiao The Sydney Morning Herald on 18 October 2019 reported that former CSL employee Dr Joseph Chiao ‘stole patient data’. CSL...

Global biotechnology leader, CSL, celebrated the Company’s 25th Anniversary of listing on the Australian Securities Exchange (ASX), commemorating the occasion with a ceremonial bell ring at...

Two Australian scientists have each been awarded AUD$1.25 million CSL Centenary Fellowships over five years to improve treatments for two of the world’s biggest health challenges: malaria and...

Major landmark development will significantly increase CSL’s presence in the Parkville biomedical precinct and cement Melbourne’s place as a world-class research destination MELBOURNE,...

MELBOURNE, Australia - CSL today announced its continued partnership with the National Youth Science Forum (NYSF) signing a new three-year agreement in support of programs that encourage life-long...

The Honourable John Brumby AO today formally opened the new ‘Nancy Millis’ building, an expansion of the Bio21 Institute of Molecular Science and Biotechnology, University of Melbourne,...

CSL spotlights developments in cell-based vaccine technology at Australian Research and Development briefing CSL Limited (ASX:CSL; USOTC:CSLLY) subsidiary Seqirus, today presented new real-world...

Two Australian scientists have each been awarded an AUD$1.25 million, five-year, CSL Centenary Fellowship to further research into why so many people die from infection following stroke and how we...

$2.5 Million Funding Available to Australian Biomedical Researchers Melbourne, Australia: 01.06.2018 - Australia’s best and brightest biomedical researchers are invited to apply for one of two...

CSL Limited today announced a revised profit outlook for fiscal 2018. CSL Limited (ASX:CSL; USOTC:CSLLY) today announced a revised profit outlook for fiscal 2018. The Company now expects net...

Dr Brian McNamee AO and Mr Abbas Hussain have been appointed as independent Non-Executive Directors, effective 14 February 2018. CSL (ASX:CSL; USOTC:CSLLY) today announced that Dr Brian McNamee AO...

CSL Behring today announced that it has signed an agreement with the National Blood Authority, representing all Australian governments, to continue to provide the community with a world-class and...

CSL today officially opened a new AUD$230 million advanced manufacturing facility at its CSL Behring site in Broadmeadows with the assistance of Victorian Minister for Industry and Employment, Ben...

The study will be the largest ever undertaken by CSL, and will enroll more than 17,000 patients from approximately 1,000 sites around the world. Jemimah Pentland 05 Dec 2017 Global biotherapeutics...

Two Australian scientists have each been awarded an AUD$1.25 million, five-year, CSL Centenary Fellowship to further research into gentler, more effective cancer diagnostics and, to advance...

Australia’s biomedical researchers are invited to apply for one of two CSL Centenary Fellowships each worth $1.25million over five years in support of discovery and translational medical...

An international team of scientists in collaboration with global biotechnology leader CSL has successfully prevented the progression of Diabetic Kidney Disease (DKD) in laboratory studies of type...